return equiti ttm
over-the-top bullish thesi stabil acceler top
intact balanc build
abbott post strong first-quart result report revenu billion come
roughli million billion target compar oper basi
exclud amo rapid diagnost foreign exchang impactrevenu growth
constant-curr basi point better model growth vast
major beat came nutrit diagnost diabet headwind
intern nutrit stabil abbott start see benefit new
product launch flu season strong adjust ep high
end guidanc rang surprisingli chang
guidanc call oper revenu growth ep
growth
highlight view quarter includ
oper epd growth arguabl within guidanc high singl digit
deceler bit seen fourth quarter believ
high expect given bullish commentari last quarter call
double-digit grower easili sustain basi
headwind relat pull forward russia help price
headwind mexico lack visibl intra-countri dynam busi
remain bit black box see improv growth rate later year new
compani new product launch continu go well libr alin lead
way invest made support sustain growth busi
import notic allow new product launch long runway
invest growth sustain key part upgrad earlier year
nutrit stabil growth better low-single-digit quarterli
guidanc manag remain optimist compani perform better
time invest faster subseg market
aler integr go well compani saw good quarter term
revenu due pickup flu sale given worst flu season past
decad upsid surpris could better manufactur
problem cent accret remain intact
cash balanc continu grow debt continu fall push
leverag manag roughli year end start
convers capit alloc potenti even manag signal
noth front burner right
abbott highli diversifi provid medic devic nutrit pharmaceut product
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
valuat stock thought
look forward pipelin new product launch gain traction acceler top-lin growth
synergi larg transact appear play least well expect combin believ
gener stabl strong perform variou organ busi abbott set top-tier revenu
earn growth ad on-going de-lever flexibl bring capit alloc discuss
later year along hundr million dollar increment sale market spend thank
upsid perform lower tax rate durabl growth appear sound reason along
still quit reason valuat time ep estim continu recommend purchas
diabet overal sale growth compar oper basi ahead estim primarili
driven strong sale freestyl libr particularli intern market result quarter strong
compani continu see new patient adopt libr patient instal base versu
last quarter believ rate patient addit outsid unit state step rel prior quarter
manag histor suggest libr ad net intern patient per quarter acceler
new patient addit like due increas reimburs coverag outsid unit state cost tend larg
driver patient interest still compani coverag two-third intern market
first four month market unit state compani seen usag patient line
modestli expect regard mix manag state libr instal base unit state thought
mix two-third type patient one-third type patient repres slight shift histor type
type mix patient addit balanc new patient competit win view commentari
posit indic libr expand glucos monitor market benefici player space
manag bullish potenti libr billion-plu world-wide franchis end littl
million patient platform overal view like achiev given strong interest
platform domest intern longer term growth like sustain new featur ad
product market adopt monitor product acceler note libr one product launch
manag expect invest sale market year product launch unit state still
manag see good leverag digit market libr could allow abbott see larger benefit
sale growth versu estim strong despit capac constraint
abbott experienc certain countri may continu temporarili affect new patient addit spring
research suggest abbott limit sensor sale patient unit kingdom smaller
countri allow exist custom purchas maximum two sensor per order everi day
buy on-line sensor life outsid unit state day constraint still allow patient order
enough use though may affect brand percept particularli occasion sensor fail earlier
expect still manag note largest market includ unit state germani
affect restrict
april post announc libr websit would close new patient juli could
extend countri depend capac constraint affect compani larger market
note expect extra capac on-line near futur
domest sale grew line estim mainli function broader launch libr unit
state manag believ launch track ahead expect expect product track gener
million million sale compani origin expect base current trajectori
patient add believ achiev though look updat reimburs payer coverag
patient churn rate past high intern libr cover medicar commerci
pharmaci plan believ ramp-up healthi could like achiev
manag note insur compani within day libr receiv fda approv
began cover product durabl medic equip dme benefit compani roughli
commerci live cover pharmaci benefit two larger insur compani sever smaller one
brought last month expect continu pharmaci win larger driver adopt
major patient current pay cash system roughli per three sensor month
equat year even dme benefit patient end pay similar amount pocket
pharmaci benefit patient like pay closer per three sensor month year
continu believ libr low cost price structur lack alarm could appeal broadli
larg type market prove somewhat true alreadi given initi mix domest patient could
prove market expans believ mani million insulin-depend type patient
unit state flash/continu monitor devic today
cardiac rhythm manag total sale flat compar oper basi line
expect driven better-than-expect intern oper result domest sale face easier
comp result came million lower expect re-impl replac can lead opportun
headwind batteri issu caus re-impl pull forward
knew potenti risk result near term expect issu prove transient result
rest year bolster abbott abil ramp recaptur share mri-saf icd fortifi assura
ellips pacemak assur crt-d quadra assura fact manag comment well de novo
implant view encourag compani approv mri-saf crt-p remain pend manag
note expect approv toward end year still market twice size pacemak market
billion make rel import market compani
model total revenu billion assum domest growth includ benefit
new mri-saf portfolio favor comparison especi second third quarter year
neuromodul domest growth compar estim roughli million ahead model
tough comp intern oper revenu growth tough oper comp
better estim believ quarter growth midteen market growth though note
comp remain difficult throughout rest year core domest busi still believ compani
continu see above-market growth db grew world-wide quarter annual modest sale
estim db sale million model domest growth second quarter
domest growth full year
burst believ burst help abbott gain roughli basi point share billion domest market
estim compani held roughli share end share
howev expect growth moder compani annual initi product launch comp becom
difficult believ abbott abl maintain gain share come year momentum new
waveform tonic continu climb
infin db abbott enter million deep brain stimul market octob thu face
difficult db comp throughout believ compani make good progress take share largest
competitor market outperform gain continu near term
heart failur domest heart failur growth came million lower expect mainli abbott
heartmat yet approv destin therapi dt indic therefor categori grew
low singl digit manag expect left ventricular assist devic lvad sale flat modestli rest
year compani receiv dt indic like later year
end march abbott announc initi new cardiomem random control trial look evalu
improv surviv outcom devic trial look enrol patient build clinic
experi previou champion trial like take one two year enrol anoth year gain
follow-up trial size like see readout trial end decad though could see
interim look still believ could gener evid need product get broader
reimburs coverag allow cardiomem larger revenu driver futur recal st jude tri
get ncd cardiomem place sinc earli ncd submit end januari request
addit data product late
nutrit overal world-wide nutrit sale grew oper quarter estim
strength larg result intern sale pediatr adult nutrit segment manag believ
market stabil believ compani maintain improv growth full-year guidanc call
low-single-digit growth come already-impl regul other
investments/strateg decis comp rest year remain similar first quarter suggest low-
midsingle-digit growth achiev
pediatr nutrit oper quarter estim improv
sequenti expect continu busi outsid unit state dynam china stabil
growth organ constant-curr fastest growth rate busi report year
albeit easi comp new regul china implement begin year overal
believ intern pediatr nutrit growth remain midsingle-digit rang domest sale
pediatr segment grew quarter versu estim believ low- midsingle-digit growth
unit state achiev throughout though compani annual product launch drove
solid growth second quarter toughest comp year compani launch new product
may continu drive above-market growth time
adult nutrit post oper domest growth quarter versu estim albeit
easier oper comp year-ago period manag activ spend categori new
formul come see better growth result expect perform continu get better
throughout year particularli given favor comparison next two quarter softer demand due
privat label product gain traction market model world-wide sale growth full
establish pharmaceut epd oper growth quarter estim weaker-
than-expect result part stem weak russia epd sale compani pharmaceutical-bas
sale face inventori challeng number pharmaci locat expand faster prescript prior
inventori build-up burn slow sale dynam like continu pressur sale russia
second quarter normal second half year manag also discuss see distributor
consolid mexico drove price pressur though mexico repres epd sale
establish pharmaceut volatil past report midsingle-digit growth first half
acceler midteen growth second half multipl emerg market geographi chang
regul market dynam still busi heavili expos emerg market sever macro
tailwind includ age popul expand middl class grow healthcar system increas healthcar
spend overal epd remain someth black box believ high-single-digit growth remain reason
compani continu expand product offer note second quarter repres easier comp year-ago
quarter affect india good servic tax tune million
includ russia key emerg market segment grew exclud russia key emerg market segment like
grew rang india china brazil continu grow double-digit rang
diagnost first-quart compar oper revenu growth beat estim base better-than-
estim gain molecular core lab rapid diagnost aler overal level growth repres favor
quarter overal diagnost franchis albeit bit less think busi grow longer term
addit believ stronger-than-expect aler number signal bit earli benefit stabil effort along
nice bump stronger flu season
laboratori first-quart revenu grew organ basi comp beat target
basi point william blair estim fuel market share gain manag commentari
remain bullish multi-year launch alin system recent acceler roll-out europ
expans test menu time launch note blood screen system full menu right clinic
chemistri immunoassay system probabl work long-term contract estim
account come contract renew year incumb win rate would impli
roughli market share chang hand year believ abbott posit favor share win
would expect see grow modestli low- midsingle-digit market growth rate observ end-
market within core lab segment
point oper growth miss target basi point estim due flat sale
unit state compar estim growth flat growth domest driven tough
comparison first quarter revenu inflat due mileston payment relat product
compani develop partner intern growth organ driven continu
uptak i-stat handheld system
molecular diagnost revenu quarter grew organ well target declin beat
target overal rate remain mute due certain product line exit mainli unit state despit higher
growth compani infecti diseas test area commentari manag previous
announc plan move sti market wrote last quarter compani make move think
alin molecular system make signific dent market domin well-establish
entrench player outperform /cepheid roch rhhbi
outperform outperform
rapid diagnost aler revenu million beat target million back strong sale associ
strong influenza season well quicker anticip integr effort addit compani see
upsid product under-market aler spend signific amount develop product
refresh improv project segment regard outlook aler asset
compani continu expect sale slightli billion despit stronger anticip
quarter interestingli area call biggest potenti headwind on-going tariff disput
unit state china total manag see potenti tariff headwind busi
full year
overal believ diagnost continu grow nice mid- high-single-digit rang line slightli
better end-market quarter lower end rang new product refresh exist
product alin make achiev still caution investor think diagnost becom
driver outsiz growth compani
model updat updat model accord manag guidanc guidanc would impli
basi point oper margin expans even pension account chang neg
gross margin impact aler acquisit compani plan reinvest
sale rais sale estim billion compar previous billion
earn full-year earn per share estim previou estim
sale increas sale estim billion compar previous billion
earn full-year earn per share estim previou estim
